Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive ...

Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. In final draft ...

Okta, Inc. , the leading independent Identity partner, today announced that it will webcast the Opening Keynote of Oktane and Investor Summit on October 16, 2024. Each presentation will be webcast ...

Chair of VHL UK/Ireland, Graham Lovitt, said: “We are delighted by NICE’s recommendation of belzutifan (Welireg) under the managed access agreement, a significant milestone in the fight agains ...

On October 14, 2024, MRK announced a clinical development collaboration with Exelixis to evaluate the investigational drug ...

Treatment with belzutifan (Welireg) showed significant benefits over everolimus (Afinitor) for advanced RCC, enhancing PFS and objective response rate (ORR). However, the LITESPARK-005 trial ...

Cabometyx, which is firmly established in the kidney cancer market, is expected to face limited growth opportunities moving forward, particularly due to emerging competition from drugs like Welireg.